T. Rowe Price Associates’s ADMA Biologics ADMA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $39M | Buy |
2,139,240
+28,309
| +1% | +$516K | ﹤0.01% | 794 |
|
|
2025
Q1 | $41.9M | Buy |
2,110,931
+10,293
| +0.5% | +$204K | 0.01% | 769 |
|
|
2024
Q4 | $36M | Buy |
2,100,638
+504
| +0% | +$8.64K | ﹤0.01% | 850 |
|
|
2024
Q3 | $42M | Buy |
2,100,134
+23,806
| +1% | +$476K | ﹤0.01% | 805 |
|
|
2024
Q2 | $23.2M | Buy |
2,076,328
+2,015,404
| +3,308% | +$22.5M | ﹤0.01% | 920 |
|
|
2024
Q1 | $403K | Buy |
60,924
+7,450
| +14% | +$49.3K | ﹤0.01% | 2293 |
|
|
2023
Q4 | $242K | Buy |
53,474
+5,506
| +11% | +$24.9K | ﹤0.01% | 2464 |
|
|
2023
Q3 | $172K | Buy |
47,968
+6,101
| +15% | +$21.9K | ﹤0.01% | 2545 |
|
|
2023
Q2 | $155K | Buy |
41,867
+2,118
| +5% | +$7.84K | ﹤0.01% | 2590 |
|
|
2023
Q1 | $132K | Buy |
39,749
+7,920
| +25% | +$26.3K | ﹤0.01% | 2629 |
|
|
2022
Q4 | $123K | Buy |
31,829
+2,986
| +10% | +$11.5K | ﹤0.01% | 2673 |
|
|
2022
Q3 | $71K | Buy |
28,843
+11,109
| +63% | +$27.3K | ﹤0.01% | 2784 |
|
|
2022
Q2 | $35K | Buy |
+17,734
| New | +$35K | ﹤0.01% | 2889 |
|